Sol-Gel Technologies

Sol-Gel Technologies Ltd. is a clinical-stage dermatology company, which engages in the identification, development, and commercialization of topical dermatological drug products for the treatment of skin diseases. Its products include VERED, TWIN, and SIRS-T. The company was founded by David Avnir and Alon Seri-Levy on October 28, 1997 and is headquartered in Ness Ziona, Israel.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Sol-Gel Technologies Ltd. operates as a clinical-stage dermatology company, which engages in the identification, development, and commercialization of topical dermatological drug products for the treatment of skin diseases. Its products include VERED, TWIN, and SIRS-T. The company was founded by David Avnir and Alon Seri-Levy on October 28, 1997 and is headquartered in Ness Ziona, Israel.

NESS ZIONA, Israel, Sept.  08, 2020  (GLOBE NEWSWIRE) -- Sol-Gel Technologies (NASDAQ: SLGL), (“Sol-Gel”), a clinical-stage dermatology company focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases, today announced that the company will present at the following upcoming virtual investor conferences.

Sol-Gel to Present at Upcoming Healthcare Investor Conferences in September

NESS ZIONA, Israel, Sept.  03, 2020  (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a clinical-stage dermatology company focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases, today announced that Bausch Health Companies, Inc. (NYSE:BHC) initiated patent infringement action in the U.S. District Court for the District of New Jersey on August 31, 2020 with regards to Perrigo Company plc (“Perrigo”) (NYSE; TASE: PRGO) Abbreviated New Drug Application (“ANDA”) for a generic version of Duobrii® (halobetasol propionate and tazarotene) lotion, for the treatment of plaque psoriasis in adults1.

Sol-Gel Technologies Collaboration Partner Filed First-to-File Paragraph IV Certification for Duobrii®

NESS ZIONA, Israel, Aug.  06, 2020  (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a clinical-stage dermatology company focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases, today announced financial results for the second quarter ended June 30, 2020 and provided clinical and regulatory updates on its programs.

Sol-Gel Technologies Reports Second Quarter 2020 Financial Results and Corporate Update

NESS ZIONA, Israel, July  29, 2020  (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL) (“Sol-Gel” or the “Company”), a clinical-stage dermatology company focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases, will report second quarter 2020 financial results on Thursday, August 6, 2020 at 7:05 AM ET.

Sol-Gel Technologies to Report Second Quarter 2020 Financial Results on August 6, 2020

NESS ZIONA, Israel, July  28, 2020  (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a clinical-stage dermatology company focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases, today announced that Sol-Gel has been informed by its collaboration partner that the launch of an FDA-approved generic drug is expected in the second quarter of 2021. In 2019, sales of the brand name product exceeded $180 million in the United States. Per terms of the previously announced collaboration agreement, Sol-Gel will receive payments based on product sales beginning at the launch date.

Sol-Gel Technologies Partnered Generic Product Expected to Launch in the Second Quarter of 2021

Generic Product Collaborations between the Companies Now Cover Ten Products Generic Product Collaborations between the Companies Now Cover Ten Products

Sol-Gel Technologies Announces Agreements with Perrigo Company for Three New Generic Product Candidates

NESS ZIONA, Israel, June  16, 2020  (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL) (“Sol-Gel” or the “Company”), a clinical-stage dermatology company focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases, today announced the company will present at the BMO 2020 Prescriptions for Success Healthcare Conference.        

Sol-Gel to Present at Virtual BMO 2020 Prescriptions for Success Healthcare Conference

NESS ZIONA, Israel, May  14, 2020  (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a clinical-stage dermatology company focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases, today announced financial results for the first quarter ended March 31, 2020 and provided an update on its clinical development programs.

Sol-Gel Technologies Reports First Quarter 2020 Financial Results and Corporate Update

Investment is for ordinary shares and warrants to purchase ordinary shares at a combined price of $11 per ordinary share and accompanying warrants to purchase 0.80 of an ordinary share

Sol-Gel Technologies Announces Closing of Additional $5.0 Million Investment

NESS ZIONA, Israel, Feb.  14, 2020  (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL) (“Sol-Gel” or the “Company”), a clinical-stage dermatology company focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases, today announced the pricing of its underwritten public offering (the “Offering”) of 2,091,907 ordinary shares together with ordinary share warrants (the “warrants”) to purchase 1,673,525 ordinary shares. The ordinary shares and accompanying warrants are being sold together at a combined public offering price of $11.00 per ordinary share and accompanying warrant. Each warrant sold in the Offering will be exercisable for 0.80 of an ordinary share, and have an initial exercise price of $14.00 per share, subject to certain adjustments. The warrants will be immediately exercisable and will expire on February 19, 2023. All of the ordinary shares and accompanying warrants are being offered by Sol-Gel.

Sol-Gel Announces Pricing of Public Offering of Ordinary Shares and Warrants to Purchase Ordinary Shares

Successful topline results, strengthens Epsolay’s long-term safety and tolerability profile in the treatment of papulopustular rosacea

Sol-Gel Announces Positive Topline Results from Open-Label, Long-Term Safety Study of Epsolay® for Treatment up to 52 Weeks

Sol-Gel Technologies: A Promising Small-Cap Dermatology Player In 2020

NESS ZIONA, Israel, Feb.  05, 2020  (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL) (“Sol-Gel” or the “Company”) a clinical-stage dermatology company focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases today provided a pipeline update and anticipated milestones for 2020.

Sol-Gel Provides Product Pipeline Updates and Anticipated Milestones for 2020

The under-the-radar pharma company might have one of the industry's more promising approaches to dermatology treatments.

Is Sol-Gel Technologies a Buy?

Sol-Gel Shines In Treating 2 Skin Disorders, NDAs Expected For Both Indications In 2020

NESS ZIONA, Israel, Jan.  02, 2020  (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL) today announced the initiation of a Phase 1 proof of concept clinical study of SGT-210, its novel, topical, epidermal growth factor receptor inhibitor in patients with punctate palmoplantar keratoderma type -1 (PPPK type 1), a genetic form of PPK.  Top-line data is expected in the first half of 2021.

Sol-Gel Announces Initiation of SGT-210 Phase 1 Proof of Concept Study  in Palmoplantar Keratoderma (PPK)

The small-cap company announced promising results from a clinical trial.

Here's Why Sol-Gel Technologies Stock Is Soaring Today

Sol Gel Technologies (SLGL) news for Monday concerning an acne drug study with incredibly positive results has SLGL stock taking off.
The post Sol Gel Technologies News: SLGL Stock Skyrockets 80% on Acne Drug Study appeared first on InvestorPlace.

Sol Gel Technologies News: SLGL Stock Skyrockets 80% on Acne Drug Study

Shares of the Israel-based, clinical-stage dermatology company Sol Gel Technologies Ltd (NASDAQ: SLGL) were more than doubling Monday.

Why Sol-Gel Shares Are Ripping Higher

Shares of Sol-Gel Technologies Ltd. SLGL, -5.82% gained 154% in premarket trading on Monday after the Israeli drugmaker said its acne drug Twyneo met the primary endpoints in two late-stage trials.

Sol-Gel stock rockets on positive data from acne study

NESS ZIONA, Israel, Dec.  30, 2019  (GLOBE NEWSWIRE) --  Sol-Gel Technologies, Ltd. (NASDAQ: SLGL) today announced top-line results from two pivotal Phase 3 clinical trials for Twyneo®, an investigational, combination of microencapsulated tretinoin 0.1% and microencapsulated benzoyl peroxide 3% cream, which demonstrated statistically significant improvement on all co-primary endpoints in the treatment of patients with acne vulgaris. Twyneo was also found to be well-tolerated.

Sol-Gel Announces Positive Top-Line Phase 3 Trial Results of Twyneo® for the Treatment of Acne Vulgaris

NESS ZIONA, Israel, Oct.  16, 2019  (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL) today announced it will present research on the use of its proprietary microencapsulation technology in treating papulopustular rosacea, including Phase 3 results for Epsolay® microencapsulated benzoyl peroxide cream, 5% (E-BPO), at the 39th Annual Fall Clinical Dermatology Conference® October 17-20 in Las Vegas, Nevada.

Sol-Gel to Present on Potential of Sol-Gel Microencapsulation Technology in Rosacea at 39th Annual Fall Clinical Dermatology Conference

Sol-Gel Technologies Ltd. (SLGL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report.

Sol-Gel Technologies Ltd. (SLGL) May Report Negative Earnings: Know the Trend Ahead of Q2 Release

Sol-Gel Technologies Ltd.  said Monday that two late-stage trials of a treatment for papulopustular rosacea produced positive results.

News for Sol-Gel Technologies Stock (SLGL)